Effects of tenofovir on cytokines and nucleotidases in HIV-1 target cells and the mucosal tissue environment in the female reproductive tract

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 11, 2014, Pages 6444-6453

  Biswas, Nabanita ^a   Rodriguez Garcia, Marta ^a   Shen, Zheng ^a   Crist, Sarah G ^a   Bodwell, Jack E ^a   Fahey, John V ^a   Wira, Charles R ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5' NUCLEOTIDASE; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; TENOFOVIR; TUMOR NECROSIS FACTOR ALPHA; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CCL20 PROTEIN, HUMAN; CD14 ANTIGEN; CYTOKINE; IL8 PROTEIN, HUMAN; PHOSPHONIC ACID DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTICLE; BIOLOGICAL ACTIVITY; CD14 T CELL; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOSE RESPONSE; DRUG EFFECT; ECTOCERVIX; ENDOMETRIUM; EPITHELIUM CELL; FEMALE; FEMALE GENITAL SYSTEM; FIBROBLAST; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYSTERECTOMY; LIMIT OF DETECTION; MUCOSA; PROTEIN EXPRESSION; PROTEIN SECRETION; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE; TARGET CELL; UPREGULATION; UTERINE ENDOCERVIX; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; CELL CULTURE; CELL SURVIVAL; CYTOLOGY; DRUG EFFECTS; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; METABOLISM; MIDDLE AGED; SECRETION (PROCESS); UTERINE CERVIX;

5'-NUCLEOTIDASE; ADENINE; ADULT; AGED; ANTI-HIV AGENTS; ANTIGENS, CD14; CD4-POSITIVE T-LYMPHOCYTES; CELL SURVIVAL; CELLS, CULTURED; CERVIX UTERI; CHEMOKINE CCL20; CYTOKINES; ENDOMETRIUM; EPITHELIAL CELLS; FEMALE; FIBROBLASTS; GENE EXPRESSION; HIV-1; HUMANS; INTERLEUKIN-8; MIDDLE AGED; MUCOUS MEMBRANE; ORGANOPHOSPHONATES; REVERSE TRANSCRIPTASE INHIBITORS; TENOFOVIR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84908565386     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03270-14     Document Type: Article

References (36)

1. UNAIDS. 2012. UNAIDS report on the global AIDS epidemic: 2012. UNAIDS, Geneva, Switzerland.
2. Barnhart KT, Izquierdo A, Pretorius ES, Shera DM, Shabbout M, Shaunik A. 2006. Baseline dimensions of the human vagina. Hum. Reprod. 21:1618-1622. http://dx.doi.org/10.1093/humrep/del022.
3. WiraCR,FaheyJV. 2008.Anewstrategy to understandhowHIVinfectswomen: identification of a window of vulnerability during the menstrual cycle. AIDS 22: 1909-1917. http://dx.doi.org/10.1097/QAD.0b013e3283060ea4.
4. Wira CR, Ghosh M, Smith JM, Shen L, Connor RI, Sundstrom P, Frechette GM, Hill ET, Fahey JV. 2011. Epithelial cell secretions from the human female reproductive tract inhibit sexually transmitted pathogens and Candida albicans but not Lactobacillus. Mucosal Immunol. 4:335-342. http://dx.doi.org/10.1038/mi.2010.72.
5. Tsuno A, Nasu K, Yuge A, Matsumoto H, Nishida M, Narahara H. 2009. Decidualization attenuates the contractility of eutopic and ectopic endometrial stromal cells: implications for hormone therapy of endometriosis. J. Clin. Endocrinol. Metab. 94:2516-2523. http://dx.doi.org/10.1210/jc.2009-0207.
6. Givan AL, White HD, Stern JE, Colby E, Gosselin EJ, Guyre PM, Wira CR. 1997. Flow cytometric analysis of leukocytes in the human female reproductive tract: comparison of fallopian tube, uterus, cervix, and vagina. Am. J. Reprod. Immunol. 38:350-359. http://dx.doi.org/10.1111/j .1600-0897.1997.tb00311.x.
7. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D. 2010. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329:1168-1174. http://dx.doi.org/10.1126/science.1193748.
8. Donnell D, Baeten JM, Bumpus NN, Brantley J, Bangsberg DR, Haberer JE, Mujugira A, Mugo N, Ndase P, Hendrix C, Celum C. 2014. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J. Acquir. Immune Defic. Syndr. 66:340-348. http://dx.doi.org/10.1097/QAI.0000000000000172.
9. Balzarini J, Hao Z, Herdewijn P, Johns DG, De Clercq E. 1991. Intracellular metabolism and mechanism of anti-retrovirus action of 9-(2-phosphonylmethoxyethyl)adenine, a potent anti-human immunodeficiency virus compound. Proc. Natl. Acad. Sci. U. S. A. 88:1499-1503. http://dx.doi.org/10.1073/pnas.88.4.1499.
10. De Clercq E. 2007. Acyclic nucleoside phosphonates: past, present and future: bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: the phosphonate bridge. Biochem. Pharmacol. 73: 911-922. http://dx.doi.org/10.1016/j.bcp.2006.09.014.
11. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, Coakley DF, Lu B, Toole JJ, Cheng AK. 2004. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 292:191-201. http://dx.doi.org/10.1001/jama.292.2.191.
12. Anderson PL, Kiser JJ, Gardner EM, Rower JE, Meditz A, Grant RM. 2011. Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. J. Antimicrob. Chemother. 66:240-250. http://dx.doi.org/10.1093/jac/dkq447.
13. van der Straten A, Van Damme L, Haberer JE, Bangsberg DR. 2012. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS 26:F13-F19. http://dx.doi.org/10.1097/QAD .0b013e3283522272.
14. Microbicide Trials Network. 25 November 2011. MTN statement on decision to discontinue use of tenofovir gel in VOICE, a major HIV prevention study in women. Microbicide Trials Network, Pittsburgh, PA.
15. Bianchi V, Pontis E, Reichard P. 1986. Interrelations between substrate cycles and de novo synthesis of pyrimidine deoxyribonucleoside triphosphates in 3T6 cells. Proc. Natl. Acad. Sci. U. S. A. 83:986-990. http://dx.doi.org/10.1073/pnas.83.4.986.
16. Hunsucker SA, Mitchell BS, Spychala J. 2005. The 5=-nucleotidases as regulators of nucleotide and drug metabolism. Pharmacol. Ther. 107:1-30 http://dx.doi.org/10.1016/j.pharmthera.2005.01.003
17. Biswas N, Rodriguez-Garcia M, Crist SG, Shen Z, Bodwell JE, Fahey JV, Wira CR. 2013. Effect of tenofovir on nucleotidases and cytokines in HIV-1 target cells. PLoS One 8:e78814. http://dx.doi.org/10.1371/journal .pone.0078814.
18. Shen Z, Fahey JV, Bodwell JE, Rodriguez-Garcia M, Rossoll RM, Crist SG, Patel MV, Wira CR. 2013. Estradiol regulation of nucleotidases in female reproductive tract epithelial cells and fibroblasts. PLoS One 8:e69854. http://dx.doi.org/10.1371/journal.pone.0069854.
19. Enomoto L, Anderson PL, Li S, Edelstein CL, Weinberg A. 2011. Effect of nucleoside and nucleotide analog reverse transcriptase inhibitors on cell-mediated immune functions. AIDS Res. Hum. Retroviruses 27:47-55. http://dx.doi.org/10.1089/aid.2010.0067.
20. Melchjorsen J, Risor MW, Sogaard OS, O'Loughlin KL, Chow S, Paludan SR, Ellermann-Eriksen S, Hedley DW, Minderman H, Ostergaard L, Tolstrup M. 2011. Tenofovir selectively regulates production of inflammatory cytokines and shifts the IL-12/IL-10 balance in human primary cells. J. Acquir. Immune Defic. Syndr. 57:265-275. http://dx.doi.org/10.1097/QAI.0b013e3182185276.
21. Sachdeva RK, Wanchu A, Bagga R, Malla N, Sharma M. 2010. Effect of non-nucleoside reverse transcriptase inhibitors on cytokine, chemokine, and immunoglobulin profiles in serum and genital secretions of HIVinfected women. J. Interferon Cytokine Res. 30:299-310. http://dx.doi.org/10.1089/jir.2009.0056.
22. Zidek Z, Kmonickova E, Holy A. 2007. Secretion of antiretroviral chemokines by human cells cultured with acyclic nucleoside phosphonates. Eur. J. Pharmacol. 574:77-84. http://dx.doi.org/10.1016/j.ejphar .2007.07.024.
23. Carreno MP, Krieff C, Irinopoulou T, Kazatchkine MD, Belec L. 2002. Enhanced transcytosis of R5-tropic human immunodeficiency virus across tight monolayer of polarized human endometrial cells under proinflammatory conditions. Cytokine 20:289-294. http://dx.doi.org/10.1006/cyto.2002.2009.
24. Levinson P, Kaul R, Kimani J, Ngugi E, Moses S, MacDonald KS, Broliden K, Hirbod T. 2009. Levels of innate immune factors in genital fluids: association of alpha defensins and LL-37 with genital infections and increased HIV acquisition. AIDS 23:309-317. http://dx.doi.org/10.1097/QAD.0b013e328321809c.
25. Naranbhai V, Abdool Karim SS, Altfeld M, Samsunder N, Durgiah R, Sibeko S, Abdool Karim Q, Carr WH. 2012. Innate immune activation enhances HIV acquisition in women, diminishing the effectiveness of tenofovir microbicide gel. J. Infect. Dis. 206:993-1001. http://dx.doi.org/10.1093/infdis/jis465.
26. Rodriguez-Garcia M, Barr FD, Crist SG, Fahey JV, Wira CR. 23 April 2014. Phenotype and susceptibility to HIV infection of CD4 Th17 cells in the human female reproductive tract. Mucosal Immunol. http://dx.doi.org/10.1038/mi.2014.26.
27. Mane VP, Heuer MA, Hillyer P, Navarro MB, Rabin RL. 2008. Systematic method for determining an ideal housekeeping gene for real-time PCR analysis. J. Biomol. Tech. 19:342-347.
28. Ghosh M, Shen Z, Schaefer TM, Fahey JV, Gupta P, Wira CR. 2009. CCL20/MIP3alpha is a novel anti-HIV-1 molecule of the human female reproductive tract. Am. J. Reprod. Immunol. 62:60-71. http://dx.doi.org/10.1111/j.1600-0897.2009.00713.x.
29. Kwon JH, Keates S, Bassani L, Mayer LF, Keates AC. 2002. Colonic epithelial cells are a major site of macrophage inflammatory protein 3alpha (MIP-3alpha) production in normal colon and inflammatory bowel disease. Gut 51:818-826. http://dx.doi.org/10.1136/gut.51.6.818.
30. Schutyser E, Struyf S, Van Damme J. 2003. The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev. 14:409-426. http://dx.doi.org/10.1016/S1359-6101(03)00049-2.
31. Li Q, Estes JD, Schlievert PM, Duan L, Brosnahan AJ, Southern PJ, Reilly CS, Peterson ML, Schultz-Darken N, Brunner KG, Nephew KR, Pambuccian S, Lifson JD, Carlis JV, Haase AT. 2009. Glycerol monolaurate prevents mucosal SIV transmission. Nature 458:1034-1038. http://dx.doi.org/10.1038/nature07831.
32. Harada A, Sekido N, Akahoshi T, Wada T, Mukaida N, Matsushima K. 1994. Essential involvement of interleukin-8 (IL-8) in acute inflammation. J. Leukoc. Biol. 56:559-564.
33. Lane BR, Lore K, Bock PJ, Andersson J, Coffey MJ, Strieter RM, Markovitz DM. 2001. Interleukin-8 stimulates human immunodeficiency virus type 1 replication and is a potential new target for antiretroviral therapy. J. Virol. 75:8195-8202. http://dx.doi.org/10.1128/JVI.75.17 .8195-8202.2001.
34. Narimatsu R, Wolday D, Patterson BK. 2005. IL-8 increases transmission of HIV type 1 in cervical explant tissue. AIDS Res. Hum. Retroviruses 21:228-233. http://dx.doi.org/10.1089/aid.2005.21.228.
35. Bours MJ, Swennen EL, Di Virgilio F, Cronstein BN, Dagnelie PC. 2006. Adenosine 5=-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol. Ther. 112:358-404. http://dx.doi.org/10.1016/j.pharmthera.2005.04.013.
36. Rodriguez-Garcia M, Patel MV, Wira CR. 2013. Innate and adaptive anti-HIV immune responses in the female reproductive tract. J. Reprod. Immunol. 97:74-84. http://dx.doi.org/10.1016/j.jri.2012.10.010.